2024/09/27 08:11:55 | |
---|---|
Price | |
176.90 EUR | |
Difference | 2.43% (4.20) |
ISIN | US1598641074 |
Symbol | CRL |
Exchange | Duesseldorf |
Currency | EUR |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 9,159 EUR |
Benchmark | S&P 500 |
Bid (Bid size) | 177.05 EUR (30) |
Ask (Ask size) | 178.80 EUR (30) |
Open | 176.90 EUR |
High | 176.90 EUR |
Low | 176.90 EUR |
Close (prev. day) | 172.70 EUR |
VWAP | - |
Volume (pcs) | 0 |
Trading volume | 0.00 |
Number of trades | 1 |
Last size | 0 |
Related Futures | - |
Related Options | - |
Date | Headline | Download | |
2024/09/11 | Global Equity Ratings | ||
2024/09/05 | Global Equity Ratings | ||
2024/08/12 | Global Equity Ratings | ||
2024/07/24 | Global Equity Ratings | ||
2024/07/12 | Global Equity Ratings |
2024/09/27 08:11:55 | |
---|---|
Price | |
176.90 EUR | |
Difference | 2.43% (4.20) |
ISIN | US1598641074 |
Symbol | CRL |
Exchange | Duesseldorf |
Currency | EUR |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 9,159 EUR |
Benchmark | S&P 500 |
Bid (Bid size) | 177.05 EUR (30) |
Ask (Ask size) | 178.80 EUR (30) |
Open | 176.90 EUR |
High | 176.90 EUR |
Low | 176.90 EUR |
Close (prev. day) | 172.70 EUR |
VWAP | - |
Volume (pcs) | 0 |
Trading volume | 0.00 |
Number of trades | 1 |
Last size | 0 |
6m | 1Y | 3Y | |
Perf (%) | -29.16% | -6.57% | - |
Perf (abs.) | -71.10 | -12.15 | - |
Beta | 1.26 | 1.44 | 1.22 |
Volatility | 34.57 | 34.05 | - |
Ø price 5 days | Ø volume 5 days (pcs.) | 180.61 EUR (0) |
Ø price 30 days | Ø volume 30 days (pcs.) | 178.57 EUR (0) |
Ø price 100 days | Ø volume 100 days (pcs.) | 192.43 EUR (0) |
Ø price 250 days | Ø volume 250 days (pcs.) | 199.40 EUR (0) |
YTD High | date | 251.10 EUR (2024/03/22) |
YTD Low | date | 169.30 EUR (2024/09/09) |
52 Weeks High | date | 251.10 EUR (2024/03/22) |
52 Weeks Low | date | 153.80 EUR (2023/11/01) |
Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
Tradegate | 2024/09/26 | 22:26 | 177.45 EUR | 0.01 | 2 |
Stuttgart | 2024/09/27 | 08:03 | 176.95 EUR | 0.00 | 1 |
NYSE | 2024/09/26 | 22:00 | 198.26 USD | 121.72 | 14,127 |
Munich | 2024/09/27 | 08:02 | 176.90 EUR | 0.00 | 1 |
Frankfurt | 2024/09/27 | 08:02 | 177.00 EUR | 0.00 | 1 |
Duesseldorf | 2024/09/27 | 08:11 | 176.90 EUR | 0.00 | 1 |
Berlin | 2024/09/27 | 11:02 | 177.95 EUR | 0.00 | 4 |
CHARLES RIVER LABORATORIES INTERNATIONAL INC. |
- - |
251 Ballardvale Street - 01887 Wilmington |
Telefon: +1-781-222-6000 |
Fax: + |
E-mail: askcharlesriver@crl.com |
Charles River Laboratories International, Inc. engages in providing products and services to help pharmaceutical and biotechnology companies. It operates through the following segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. The RMS segment includes its insourcing solutions business and Charles River accelerator and development lab footprint. The DSA segment offers regulatory-required safety testing of potential new drugs, vaccines, industrial and agricultural chemicals, consumer products, veterinary medicines, and medical devices. The Manufacturing Solutions segment focuses on microbial solutions and biologics solutions. The company was founded by Henry L. Foster in 1947 and is headquartered in Wilmington, MA. |
Craig Thompson | Member of Board of Directors |
Deborah Kochevar | Member of Board of Directors |
Martin MacKay | Member of Board of Directors |
Nancy Andrews | Member of Board of Directors |
George Llado | Member of Board of Directors |
George Massaro | Member of Board of Directors |
Reshema Kemps-Polanco | Member of Board of Directors |
Richard Wallman | Member of Board of Directors |
Robert Bertolini | Member of Board of Directors |
Virginia Wilson | Member of Board of Directors |
James Foster | Chairman of Managing Board |
Birgit Girshick | Member of Executive Committee |
Flavia Pease | Member of Executive Committee |
Gina M. Mullane | Member of Executive Committee |
John C. Ho | Member of Executive Committee |
Julie Frearson | Member of Executive Committee |
Kristen M. Eisenhauer | Member of Executive Committee |
Mark Mintz | Member of Executive Committee |
Matthew L. Daniel | Member of Executive Committee |
Michael G. Knell | Member of Executive Committee |
Victoria L. Creamer | Member of Executive Committee |
Any information, material and services regarding financial instruments and securities provided by Česká spořitelna/Erste Group/ or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites“) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions.
By agreeing to this hereto, the visitor entering this Websites confirms that has read, understood and accepted this Information and the Disclaimer